|
 Research articleMutational analysis of Peroxiredoxin IV: exclusion of a positional candidate for multinodular goitreEmiliano Giardina1 1Department of Biopathology, "Tor Vergata" University of Rome, Italy 2Department of Experimental Medicine, University of Catanzaro, Italy
BMC Medical Genetics 2002, 3:5doi:10.1186/1471-2350-3-5 The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1471-2350/3/5
© 2002 Giardina et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. AbstractBackgroundMultinodular goitre (MNG) is a common disorder characterised by an enlargement of the thyroid, occurring as a compensatory response to hormonogenesis impairment. The incidence of MNG is dependent on sex (female:male ratio 5:1) and several reports have documented a genetic basis for the disease. Last year we mapped a MNG locus to chromosome Xp22 in a region containing the peroxiredoxin IV (Prx-IV) gene. Since Prx-IV is involved in the removal of H2O2 in thyroid cells, we hypothesize that mutations in Prx-IV gene are involved in pathogenesis of MNG. MethodsFour individuals (2 affected, 2 unrelated unaffected) were sequenced using automated methods. All individuals were originated from the original three-generation Italian family described in previous studies. A Southern blot analysis using a Prx-IV full-length cDNA as a probe was performed in order to exclude genomic rearrangements and/or intronic mutations. In addition a RT-PCR of PRX-IV was performed in order to investigate expression alterations. ResultsNo causative mutations were found. Two adjacent nucleotide substitutions were detected within introns 1 and 4. These changes were also detected in unaffected individuals, suggesting that they were innocuous polymorphisms. No gross genomic rearrangements and/or restriction fragment alterations were observed on Southern analysis. Finally, using RT-PCR from tissue-specific RNA, no differences of PRX-IV expression-levels were detected between affected and unaffected samples. ConclusionsBased on sequence and genomic analysis, Prx-IV is very unlikely to be the MNG2 gene. BackgroundMultinodular goiter (MNG, OMIM *138800) is a common disorder, arising as a compensatory response to an impairment of thyroid hormonogenesis. Affected individuals maintain normal hormone levels by an increase in thyroid activity and mass, so that they are eu-metabolic but goitrous [1]. Even if MNG incidence is influenced by iodine intake, family clustering of the disease has been reported in iodo-sufficient areas, suggesting a genetic basis for the disease [2]. This was confirmed by the identification of three dominant MNG loci: MNG1 on chromosome 14q [3], MNG2 on chromosome Xp22 [4] and MNG3 on chromosome 3q26 [5]. The MNG2 locus maps to a 9.6 cM interval containing the peroxiredoxin-IV (Prx-IV, formerly known as AOE372) gene. Peroxiredoxins are a family of highly conserved anti-oxidant enzymes, reducing hydrogen peroxide and/or organic hydroperoxides [6]. In thyroid cells, regulation of H2O2 concentration is critical for the thyroxine synthesis, since hydrogen peroxide is needed for the conversion of iodide to organically bound iodine. Since PRX-I e PRX-II are involved in the removal of H2O2 in thyroid cells, we have hypothesised that Prx-IV mutations may affect intracellular H2O2 levels and impair thyroxine hormonogenesis. Therefore, we have screened Prx-IV as a MNG2 positional candidate. MethodsDirect sequencingWe have sequenziated four individuals (2 affected, 2 unrelated unaffected) originated from the large family that allowed the MNG2 locus assignment [4]. Intronic primers pairs amplifying Prx-IV exons were designed (Table 1), based on the genomic structure reported by Wong et al.[6]. One primers pair amplifying 500 bp of putative promoter was also selected (Table 1). Intron and 5'UTR sequences were obtained, using the BLAST program to match Prx-IV mRNA (accession n. XM_041446) against the "htgs" database of genomic sequences. The most likely location of the promoter was assessed using the SCAN SIGNAL software. PCR products were sequenced with the CEQ™ DTCS Kit (Beckman-Coulter, CA, USA) and run on a CEQ2000 automated sequencer (Beckman-Coulter, CA, USA). Table 1. Forward and reverse PCR primers used for amplification of the coding and promoter regions of PRX-IV Southern blot5 μg genomic DNA were digested using EcoRI and Hind III. Digests were electrophoresed on 1.0% agarose gels, and the DNA was subsequently transferred to Hybond N+ filter membranes (Amersham), with 10 × SSC as transferring buffer. Probes were labeled, by random priming, with 32P-dCTP. Membranes were hybridized overnight at 65°C. Final washing of the membranes was performed with 0.1 × SSC at 65°C. The results were analyzed with the STORM Phosphor Imaging System. FNAB and RT-PCRPatients were placed in the recumbent position with a pillow under their shoulders, such that their neck was hyperextended, and the skin cleansed with povidone iodine (Betadina scrub). The nodules was fixed in position manually, and a 23 gauge needle attacched to a 20 ml disposable syringe inserted perpendicular to the anterior surface of the neck. Once the needle was in place, costant suction was applied and maintained while the needle was withdrawn to the level of the nodules capsule. The content was then discharged onto glass slides and smears were made. FNAB samples were then washed twice with 1 × PBS and then processed for RNA extraction. Approximately 1 μg of RNA was incubated at 42°C for 1 hour with 2.5 μM random hexamers (Pharmacia, LKB, Uppsala), 25 U of Rnase inhibitor (Rnasin, Promega, Madison, WI), 2.5 μl of 10 mM each dNTPs, 4 μl of 5 × AMV RT (Promega, Madison, WI) in a final volume of 20 μl. The cDNA was next amplified by PCR for PRX-IV gene using primers showed in table 1. As a positive control we coamplified the constitutively expressed enzyme glyceraldeide 3-phosphate dehydrogenase (GAPDH). The intensity of the amplified fragments was compared by scanning using a Molecular Dynamics (Sunnyvale, CA) densitometer (ImageQuant). ResultsWe have carried out Prx-IV mutational analysis in the three-generation Italian pedigree that allowed the MNG2 locus assignment [4]. Prx-IV is a cytoplasmatic thioredoxin peroxidase that detoxifies hydrogen peroxide in a redox chain leading to NADPH oxidation [7]. Therefore, Prx-IV appears an attractive MNG candidate, since thyroxine synthesis requires hydrogen peroxide. Patient sequencing identified two adjacent substitutions in intron 1 (IVS1-9G>A and IVS1-10A>T), and one in intron 4 (IVS4+81T>C). All variants were also found in one unrelated unaffected male, thus ruling out the hypothesis that any of them might be disease-related. Coding region analysis failed to detect any additional substitutions and moreover promoter region analysis didn't detect other substitutions. Since the affected females carrying both alleles at intron 2 variants, the occurrence of a large gene deletion can be excluded. In addition, as shown in figure 1, no gross PRX-IV rearrangements were detected by Southern blot analysis.
Expression analysis using amplified PRX-IV cDNA revealed a single PCR product of the expected size. An equal relative ratio of intensity with a value 0.86 was detected when this product was compared with GAPDH cDNA used as a control (Data not shown). Discussion and ConclusionsAltogether our data indicate that Prx-IV is very unlikely to be the MNG2 gene. The MNG2 region does not contain any additional obvious candidate, but many ESTs map to the critical interval. Thus, our future research will be devoted to the identification and characterization of those MNG2 ESTs that are expressed in the thyroid. List of abbreviations usedMNG : multinodular goitre PRX : peroxiredoxin EST : expressed sequence tag FNAB : fine needle aspiration biopsy Competing interestsNone declared AcknowledgementsThis work was funded by the Italian Telethon (project E1031). References
Pre-publication historyThe pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2350/3/5/prepub Have something to say? Post a comment on this article! |
|
|
|
 |  | Log on / register Feedback | Support | My details |
on Google Scholar
author email
corresponding author email
Figure 1.|
|
| © 1999-2008 BioMed Central Ltd unless otherwise stated |